Our Commitment
global health, and the planet
-
sustainable markets initiative
- Member of Sustainable Markets Initiative
-
Supply Chains Working Group championed by John Rim, CEO of Samsung Biologics
Samsung Biologics has joined as a Terra Carta Supporter with 12 other leaders from across the healthcare system
-
Member of Dow Jones Sustainability Indices Powered by the S&P Global CSA
- Listed on the DJSI World Indices
-
First Korean life science company, 2021
-
ISO
- Obtained global ISO certifications
-
- - ISO 50001 (Energy Management)
- - ISO 45001 (Occupational Health and Safety Management)
- - ISO 14001 (Effective Environmental Management)
-
FROST SULLIVAN INSTITUTE
- 2022 Enlightened Growth Leadership Award
-
Recognized for ‘innovating to zero’
- - Zero global illness
- - Zero emissions
- - Zero workplace accidents
-
Frontier 1.5D
- Participant in the Frontier 1.5D initiative
-
Developing a climate risk management model as part of 2050 Carbon Neutral Strategy
-
CDP
- 2021 B rating in CDP & “Honors Award” in carbon management sector by CDP awards
-
KCGS 한국기업지배구조원
- 2021 Grade A in ESG comprehensive evaluation
-
Environmental A
Social management A+
Corporate governance A
-
ministry of gender equality and family
- “Best Family-Friendly Management” company for 7 consecutive years
ESG Report
- 2022 ESG Report
-
Under the purpose of creating value across economic, societal, and environmental areas and disclosing ESG achievements to the stakeholders in a transparent manner, Samsung Biologics has issued the ESG report. Through the report, we aim to share our annual performances and activities transparently, collect opinions from various stakeholders, and reflect such opinions in our business activities in a bid to enhance the effectiveness of our ESG management practices.
2022 ESG Report
- Reporting Period
-
The report covers the period of January 1st, 2021 to December 31st, 2021, but may include significant events dating up to the first half of 2022. Quantitative data for the past three fiscal years from 2019 to 2021 (with some environmental data for four years from 2018 to 2021) has been provided to allow for trend analysis over time.
- Reporting Standards
-
This report was prepared in accordance with the Core option of the Global Reporting Initiative (GRI) standards, global reporting standards for sustainability management. It also used ISO 26000, UN Global Compact principles,
Framework, SASB information disclosure standards, and TCFD recommendations as references.
- Reporting Scope
-
This report covers the sustainability activities and performances of all domestic and international businesses. Financial data is based upon consolidated K-IFRS. In addition to financial information, non-financial information has followed our formal disclosure system and has been prepared in accordance with the fiscal year, and the data related to energy usage and greenhouse gas emissions were prepared in accordance with the results of the emission verification.
Marketing Practices
Samsung Biologics endeavors that our marketing activities and materials to promote services and products comply with ethical, medical, and scientific standards as well as applicable laws and regulations. When engaging with healthcare professionals, patients, and business partners, Samsung Biologics will abide by relevant industry standards of conduct.
